DUBLIN--(BUSINESS WIRE)--

Research and Markets has announced the addition of the "MediPoint: Predictive Breast Cancer Gene Testing - US Analysis and Market Forecasts" report to their offering.

Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due to the increased life span and increasing adoption of Western lifestyle risk factors. Predictive breast cancer gene tests can be used to identify women who are at increased risk of developing hereditary breast cancer. The Predictive Breast Cancer Gene Testing market has seen exponential growth in the US, dominated by Myriad Genetics. Gene testing in Europe is mostly carried out by the state funded health sector, but increasingly private companies are offering breast cancer gene tests to physicians. Myriad Genetics' position in the market is dependent on it being the leading provider of the most common breast cancer mutations. By the end of our forecast period, the competitive landscape will experience significant change due to the erosion of Myriad Genetics' position, as a result of the expiry of key patents, and the emergence of alternative molecular technologies.

This report focuses on the predictive breast cancer gene testing markets in the US and identifies unmet needs in the market, physician attitudes towards current gene testing, and the future of gene testing in the face of rapid technological advancement.

Reasons to buy

- Understand the trends shaping and driving the US Breast Cancer Gene Testing Market.

- Realize device preferences of physicians who have performed the tests already.

- Access market sizing, forecasts and quantified growth opportunities in the US Breast Cancer Gene Testing Market through 2018.

- Quantify candidate patient populations to better design product pricing & launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.

Continue reading here:
Research and Markets: MediPoint Report: Predictive Breast Cancer Gene Testing - US Analysis and Market Forecasts 2013 ...

Comments are closed.